|
1
|
Bitton A, Vutcovici M, Patenaude V,
Sewitch M, Suissa S and Brassard P: Epidemiology of inflammatory
bowel disease in Quebec: Recent trends. Inflamm Bowel Dis.
20:1770–1776. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bashashati M, Rezaei N, Andrews CN, Chen
CQ, Daryani NE, Sharkey KA and Storr MA: Cytokines and irritable
bowel syndrome: Where do we stand? Cytokine. 57:201–209.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cosnes J, Gower-Rousseau C, Seksik P and
Cortot A: Epidemiology and natural history of inflammatory bowel
diseases. Gastroenterology. 140:1785–1794. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ananthakrishnan AN: Epidemiology and risk
factors for IBD. Nat Rev Gastroenterol Hepatol. 12:205–217.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Beaugerie L and Itzkowitz SH: Cancers
complicating inflammatory bowel disease. N Engl J Med.
372:1441–1452. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fichtner-Feigl S, Strober W, Geissler EK
and Schlitt HJ: Cytokines mediating the induction of chronic
colitis and colitis-associated fibrosis. Mucosal Immunol. 1 (Suppl
1):S24–S27. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rungoe C, Nyboe Andersen N and Jess T:
Inflammatory bowel disease and risk of coronary heart disease.
Trends Cardiovasc Med. 25:699–704. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nyuyki KD and Pittman QJ: Toward a better
understanding of the central consequences of intestinal
inflammation. Ann NY Acad Sci. 1351:149–154. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Levesque BG, Sandborn WJ, Ruel J, Feagan
BG, Sands BE and Colombel JF: Converging goals of treatment of
inflammatory bowel disease from clinical trials and practice.
Gastroenterology. 148:37–51 e1. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fonseca-Camarillo G and Yamamoto-Furusho
JK: Immunoregulatory pathways involved in inflammatory bowel
disease. Inflamm Bowel Dis. 21:2188–2193. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Koelink PJ, Overbeek SA, Braber S, de
Kruijf P, Folkerts G, Smit MJ and Kraneveld AD: Targeting chemokine
receptors in chronic inflammatory diseases: An extensive review.
Pharmacol Ther. 133:1–18. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mitroulis I, Alexaki VI, Kourtzelis I,
Ziogas A, Hajishengallis G and Chavakis T: Leukocyte integrins:
Role in leukocyte recruitment and as therapeutic targets in
inflammatory disease. Pharmacol Ther. 147:123–135. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Merga Y, Campbell BJ and Rhodes JM:
Mucosal barrier, bacteria and inflammatory bowel disease:
Possibilities for therapy. Dig Dis. 32:475–483. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen SJ, Liu XW, Liu JP, Yang XY and Lu
FG: Ulcerative colitis as a polymicrobial infection characterized
by sustained broken mucus barrier. World J Gastroenterol.
20:9468–9475. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhu Y, Mahon BD, Froicu M and Cantorna MT:
Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha
pathway to suppress experimental inflammatory bowel disease. Eur J
immunol. 35:217–224. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Danese S, Sans M, Scaldaferri F, Sgambato
A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A
and Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L
pathway in the mucosal microcirculation: A novel anti-inflammatory
mechanism of infliximab in Crohn's disease. J Immunol.
176:2617–2624. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Condino G, Calabrese E, Zorzi F, Onali S,
Lolli E, De Biasio F, Ascolani M, Pallone F and Biancone L:
Anti-TNF-alpha treatments and obstructive symptoms in Crohn's
disease: A prospective study. Dig Liver Dis. 45:258–262.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pugliese D, Guidi L, Ferraro PM, Marzo M,
Felice C, Celleno L, Landi R, Andrisani G, Pizzolante F, De Vitis
I, et al: Paradoxical psoriasis in a large cohort of patients with
inflammatory bowel disease receiving treatment with anti-TNF alpha:
5-year follow-up study. Aliment Pharmacol Ther. 42:880–888.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ikemoto SK, Yoshida N, Yasumoto R, Wada S,
Yamamoto K and Kishimoto T: Antitumor effects of Scutellariae radix
and its components baicalein, baicalin, and wogonin on bladder
cancer cell lines. Urology. 55:951–955. 2000.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sun SJ, Wu XP, Song HL and Li GQ: Baicalin
ameliorates isoproterenol-induced acute myocardial infarction
through iNOS, inflammation, oxidative stress and P38MAPK pathway in
rat. Int J Clin Exp Med. 8:22063–22072. 2015.PubMed/NCBI
|
|
21
|
Li X, Zou K, Gou J, Du Q, Li D, He X and
Li Z: Effect of baicalin-copper on the induction of apoptosis in
human hepatoblastoma cancer HepG2 cells. Med Oncol.
32(72)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Guo X, Chi S, Cong X, Li H, Jiang Z, Cao R
and Tian W: Baicalin protects sertoli cells from heat
stress-induced apoptosis via activation of the Fas/FasL pathway and
Hsp72 expression. Reprod Toxicol. 57:196–203. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zou Y, Dai SX, Chi HG, Li T, He ZW, Wang
J, Ye CG, Huang GL, Zhao B, Li WY, et al: Baicalin attenuates
TNBS-induced colitis in rats by modulating the Th17/Treg paradigm.
Arch Pharm Res. 38:1873–1887. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu X, Gu J, Fan Y, Shi H and Jiang M:
Baicalin attenuates acute myocardial infarction of rats via
mediating the mitogen-activated protein kinase pathway. Biol Pharm
Bull. 36:988–994. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lin M, Li L, Li L, Pokhrel G, Qi G, Rong R
and Zhu T: The protective effect of baicalin against renal
ischemia-reperfusion injury through inhibition of inflammation and
apoptosis. BMC Complement Altern Med. 14(19)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cui L, Feng L, Zhang ZH and Jia XB: The
anti-inflammation effect of baicalin on experimental colitis
through inhibiting TLR4/NF-κB pathway activation. Int
Immunopharmacol. 23:294–303. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang Y, Li X, Ciric B, Ma CG, Gran B,
Rostami A and Zhang GX: Therapeutic effect of baicalin on
experimental autoimmune encephalomyelitis is mediated by SOCS3
regulatory pathway. Sci Rep. 5(17407)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Morris GP, Beck PL, Herridge MS, Depew WT,
Szewczuk MR and Wallace JL: Hapten-induced model of chronic
inflammation and ulceration in the rat colon. Gastroenterology.
96:795–803. 1989.PubMed/NCBI
|
|
29
|
Siggers RH and Hackam DJ: The role of
innate immune-stimulated epithelial apoptosis during
gastrointestinal inflammatory diseases. Cell Mol Life Sci.
68:3623–3634. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Marini M, Bamias G, Rivera-Nieves J,
Moskaluk CA, Hoang SB, Ross WG, Pizarro TT and Cominelli F:
TNF-alpha neutralization ameliorates the severity of murine
Crohn's-like ileitis by abrogation of intestinal epithelial cell
apoptosis. Proc Natl Acad Sci USA. 100:8366–8371. 2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cario E: Barrier-protective function of
intestinal epithelial Toll-like receptor 2. Mucosal Immunol. 1
(Suppl 1):S62–S66. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kaplan GG: The global burden of IBD: From
2015 to 2025. Nat Rev Gastroenterol Hepatol. 12:720–727.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Baumgart DC and Sandborn WJ: Inflammatory
bowel disease: Clinical aspects and established and evolving
therapies. Lancet. 369:1641–1657. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wirtz S, Popp V, Kindermann M, Gerlach K,
Weigmann B, Fichtner-Feigl S and Neurath MF: Chemically induced
mouse models of intestinal inflammation. Nat Protoc. 12:1295–1309.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Randhawa PK, Singh K, Singh N and Jaggi
AS: A review on chemical-induced inflammatory bowel disease models
in rodents. Korean J Physiol Pharmacol. 18:279–288. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wallace KL, Zheng LB, Kanazawa Y and Shih
DQ: Immunopathology of inflammatory bowel disease. World J
Gastroenterol. 20:6–21. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Atreya R, Mudter J, Finotto S, Müllberg J,
Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, et
al: Blockade of interleukin 6 trans signaling suppresses T-cell
resistance against apoptosis in chronic intestinal inflammation:
Evidence in Crohn disease and experimental colitis in vivo. Nat
Med. 6:583–588. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Atreya R and Neurath MF: Involvement of
IL-6 in the pathogenesis of inflammatory bowel disease and colon
cancer. Clin Rev Allergy Immunol. 28:187–196. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Atreya R and Neurath MF: New therapeutic
strategies for treatment of inflammatory bowel disease. Mucosal
Immunol. 1:175–182. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Qiu W, Wu B, Wang X, Buchanan ME, Regueiro
MD, Hartman DJ, Schoen RE, Yu J and Zhang L: PUMA-mediated
intestinal epithelial apoptosis contributes to ulcerative colitis
in humans and mice. J Clin Invest. 121:1722–1732. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lin W, Ma C, Su F, Jiang Y, Lai R, Zhang
T, Sun K, Fan L, Cai Z, Li Z, et al: Raf kinase inhibitor protein
mediates intestinal epithelial cell apoptosis and promotes IBDs in
humans and mice. Gut. 66:597–610. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zeissig S, Bojarski C, Buergel N, Mankertz
J, Zeitz M, Fromm M and Schulzke JD: Downregulation of epithelial
apoptosis and barrier repair in active Crohn's disease by tumour
necrosis factor alpha antibody treatment. Gut. 53:1295–1302.
2004.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gu L, Ge Z, Wang Y, Shen M and Zhao P:
Activating transcription factor 3 promotes intestinal epithelial
cell apoptosis in Crohn's disease. Pathol Res Pract. 214:862–870.
2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rodrigues RC, Pocheron AL, Cappelier JM,
Tresse O and Haddad N: An adapted in vitro assay to assess
Campylobacter jejuni interaction with intestinal epithelial cells:
Taking into stimulation with TNFα. J Microbiol Methods. 149:67–72.
2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gu L, Zhao J, Zhang S, Xu W, Ni R and Liu
X: Runt-related transcription factor 2 (RUNX2) inhibits apoptosis
of intestinal epithelial cells in Crohn's disease. Pathol Res
Pract. 214:245–252. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Li M, Zhang S, Qiu Y, He Y, Chen B, Mao R,
Cui Y, Zeng Z and Chen M: Upregulation of miR-665 promotes
apoptosis and colitis in inflammatory bowel disease by repressing
the endoplasmic reticulum stress components XBP1 and ORMDL3. Cell
Death Dis. 8(e2699)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Yan L, Wang L, Bai J, Miao X, Zeng W, Hua
X, Ni R, Zhang D and Tang Q: Chromosome region maintenance-1 (CRM1)
regulates apoptosis of intestinal epithelial cells via p27kip1 in
Crohn's disease. Clin Res Hepatol Gastroenterol. 41:445–458.
2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Baròn M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Chen W, Liu Y, Xue G, Zhang L, Zhang L and
Shao S: Diazoxide protects L6 skeletal myoblasts from H2O2-induced
apoptosis via the phosphatidylinositol-3 kinase/Akt pathway.
Inflamm Res. 65:53–60. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Schulzke JD, Ploeger S, Amasheh M, Fromm
A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M and
Fromm M: Epithelial tight junctions in intestinal inflammation. Ann
NY Acad Sci. 1165:294–300. 2009.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Johansson ME: Mucus layers in inflammatory
bowel disease. Inflamm Bowel Dis. 20:2124–2131. 2014.PubMed/NCBI View Article : Google Scholar
|
